Literature DB >> 9850401

Artemisinin derivatives in the treatment of falciparum malaria in pregnancy.

R McGready1, T Cho, J J Cho, J A Simpson, C Luxemburger, L Dubowitz, S Looareesuwan, N J White, F Nosten.   

Abstract

An artemisinin derivative (artesunate or artemether) was used for the treatment of multidrug-resistant Plasmodium falciparum malaria in 83 Karen pregnant women in Thailand; 55 women were treated for recrudescent infection following quinine or mefloquine, 12 for uncomplicated hyperparasitaemic episodes, and 16 had not declared their pregnancy when treated. The women were followed weekly until delivery. Artesunate and artemether were well tolerated and there was no drug-related adverse effect. Recrudescence within 42 d occurred in 16% of the treated episodes. Overall 73 pregnancies (88%) resulted in live births, 3 (4%) in abortions and 2 (3%) in still births, and 5 women were lost to follow-up before delivery. There was no congenital abnormality in any of the newborn children, and the 46 children followed for more than one year all developed normally.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850401     DOI: 10.1016/s0035-9203(98)91081-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  18 in total

1.  Malaria in Pregnancy.

Authors:  S Chawla; V Manu
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 3.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 4.  A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy.

Authors:  Christine Manyando; Kassoum Kayentao; Umberto D'Alessandro; Henrietta U Okafor; Elizabeth Juma; Kamal Hamed
Journal:  Malar J       Date:  2012-05-01       Impact factor: 2.979

5.  Evaluation and pharmacovigilance of projects promoting cultivation and local use of Artemisia annua for malaria.

Authors:  Merlin L Willcox; Shelly Burton; Rosalia Oyweka; Rehema Namyalo; Simon Challand; Keith Lindsey
Journal:  Malar J       Date:  2011-04-11       Impact factor: 2.979

6.  Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study.

Authors:  R McGready; S J Lee; J Wiladphaingern; E A Ashley; M J Rijken; M Boel; J A Simpson; M K Paw; M Pimanpanarak; Oh Mu; P Singhasivanon; N J White; F H Nosten
Journal:  Lancet Infect Dis       Date:  2011-12-12       Impact factor: 25.071

Review 7.  The safety of artemisinins during pregnancy: a pressing question.

Authors:  Stephanie Dellicour; Susan Hall; Daniel Chandramohan; Brian Greenwood
Journal:  Malar J       Date:  2007-02-14       Impact factor: 2.979

8.  Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.

Authors:  Alfredo Mayor; Elisa Serra-Casas; Azucena Bardají; Sergi Sanz; Laura Puyol; Pau Cisteró; Betuel Sigauque; Inacio Mandomando; John J Aponte; Pedro L Alonso; Clara Menéndez
Journal:  Malar J       Date:  2009-01-09       Impact factor: 2.979

9.  A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women.

Authors:  Linda Kalilani; Innocent Mofolo; Marjorie Chaponda; Stephen J Rogerson; Alisa P Alker; Jesse J Kwiek; Steven R Meshnick
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

10.  In-vitro Evaluation of Antileishmanial Activity and Toxicity of Artemether with Focus on its Apoptotic Effect.

Authors:  Parisa Ebrahimisadr; Fatemeh Ghaffarifar; Zuhair Mohammad Hassan
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.